Tag: FR:MC

Hermès Shines in a Scruffy Luxury Market
Money

Hermès Shines in a Scruffy Luxury Market

Hermès is a brand that shows its real mettle in a downturn. The secret to its steady growth might be the restraint it shows in good times.  The French handbag maker’s shares gained 33% in 2023, making it the luxury sector’s best-performing stock. Parisian rival LVMH Moët Hennessy Louis Vuitton, which owns Christian Dior and is also considered one of the safest bets in luxury, rose 8%. But across the industry, most large European luxury stocks ended 2023 in the red as demand for expensive baubles sputtered following a record three-year shopping binge.   Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Coach Saves Tapestry From Unraveling
Money

Coach Saves Tapestry From Unraveling

Luxury demand isn’t quite what it used to be. Neither is demand for accessible luxury, but it seems strong enough that brands like Coach are still able to push through price hikes.Coach owner Tapestry, which also owns Kate Spade and Stuart Weitzman, reported revenue growth of 0.4% in its quarter ended Sept. 30, weaker than Wall Street expectations of 2% growth. This follows worse-than-expected sales performance at European luxury powerhouses such as Gucci owner Kering and Louis Vuitton owner LVMH. But Tapestry’s adjusted earnings of $0.93 a share was higher than expectations of $0.90.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Ozempic Maker Novo Nordisk Has a Weight Problem
Money

Ozempic Maker Novo Nordisk Has a Weight Problem

Oct. 23, 2023 11:39 am ETThe company behind diabetes and obesity phenomena Ozempic and Wegovy is overweight.Novo Nordisk became Europe’s most valuable company last month, overtaking luxury goods maker LVMH, which itself took the title from food company Nestlé in 2021. All three companies are global stars that dominate the small European stages where they play, but the Danish drug company is now an extreme case. This might be a reason why the shares trade at a discount to those of its closest peer, U.S.-listed Eli Lilly.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8